Amylyx Pharmaceuticals (AMLX) News Today → Guard Against the Coming Financial Upheaval (From Porter & Company) (Ad) Free AMLX Stock Alerts $1.83 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 1:31 PM | insidertrades.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Gina Mazzariello Sells 10,455 SharesMay 15, 2024 | americanbankingnews.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Given New $3.00 Price Target at MizuhoMay 14, 2024 | marketbeat.comAmylyx Pharmaceuticals (NASDAQ:AMLX) PT Lowered to $3.00Mizuho reduced their price target on shares of Amylyx Pharmaceuticals from $4.00 to $3.00 and set a "neutral" rating on the stock in a research note on Tuesday.May 13, 2024 | markets.businessinsider.comBank of America Securities Keeps Their Hold Rating on Amylyx Pharmaceuticals Inc (AMLX)May 13, 2024 | americanbankingnews.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Announces Quarterly Earnings Results, Misses Estimates By $0.70 EPSMay 12, 2024 | americanbankingnews.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Rating Reiterated by HC WainwrightMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Amylyx Pharmaceuticals on Positive ALS and Wolfram Syndrome TrialsMay 10, 2024 | markets.businessinsider.comBreaking Down Amylyx Pharma: 9 Analysts Share Their ViewsMay 10, 2024 | finance.yahoo.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comAmylyx Pharmaceuticals Reports Q1 2024 Financial ResultsMay 10, 2024 | marketbeat.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Issues Earnings ResultsAmylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.70). Amylyx Pharmaceuticals had a return on equity of 12.39% and a net margin of 12.94%. The firm had revenue of $88.64 million during the quarter, compared to analyst estimates of $113.26 million. During the same period in the previous year, the company earned $0.02 earnings per share.May 10, 2024 | marketbeat.comAmylyx Pharmaceuticals' (AMLX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $8.00 target price on shares of Amylyx Pharmaceuticals in a report on Friday.May 10, 2024 | americanbankingnews.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Recommendation of "Hold" from BrokeragesMay 9, 2024 | finance.yahoo.comAmylyx Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 8, 2024 | businesswire.comAmylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care ConferenceMay 3, 2024 | marketbeat.comAmylyx Pharmaceuticals (AMLX) Scheduled to Post Earnings on ThursdayAmylyx Pharmaceuticals (NASDAQ:AMLX) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.May 2, 2024 | businesswire.comAmylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024April 17, 2024 | msn.comAmylyx Pharmaceuticals (AMLX) Price Target Decreased by 17.36% to 4.34April 12, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals: A Hold Rating Amidst Promising but Preliminary HELIOS Trial ResultsApril 11, 2024 | markets.businessinsider.comHold Rating on Amylyx Pharmaceuticals Amid Uncertainties in Drug Efficacy and Market ProspectsApril 11, 2024 | marketbeat.comRobert W. Baird Lowers Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target to $3.00Robert W. Baird reduced their price target on Amylyx Pharmaceuticals from $4.00 to $3.00 and set a "neutral" rating for the company in a research report on Thursday.April 10, 2024 | msn.comAmylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited DisorderApril 10, 2024 | finance.yahoo.comAmylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram SyndromeApril 10, 2024 | businesswire.comAmylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram SyndromeApril 9, 2024 | prnewswire.comThe Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLXApril 8, 2024 | markets.businessinsider.comOptimistic Outlook for Amylyx Pharmaceuticals Inc with AMX0035’s Potential in Rare DiseasesApril 8, 2024 | stockhouse.com48 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AmylyxApril 8, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)April 8, 2024 | businesswire.comAmylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024April 8, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals Shifts Focus: Hold Recommendation Amidst R&D Pivot and Revenue ImpactApril 8, 2024 | markets.businessinsider.comUnveiling 6 Analyst Insights On Amylyx PharmaApril 8, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX)HC Wainwright reiterated a "buy" rating and issued a $8.00 target price on shares of Amylyx Pharmaceuticals in a research note on Monday.April 8, 2024 | prnewswire.comLevi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) ShareholdersApril 6, 2024 | finance.yahoo.comAnalysts Just Slashed Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) EPS NumbersApril 5, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint - Hagens BermanApril 5, 2024 | prnewswire.comAMLX Investors Have Opportunity to Lead Amylyx Pharmaceuticals, Inc. Securities Fraud LawsuitApril 5, 2024 | prnewswire.comAmylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLXApril 4, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals: Hold Rating Maintained Amidst Drug Discontinuation and Pipeline DevelopmentsApril 4, 2024 | prnewswire.comAMLX FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLXApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - AMLXApril 4, 2024 | stockhouse.com5-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmApril 4, 2024 | bizjournals.comAmylyx withdraws ALS drug after trial fail, slashes headcountApril 4, 2024 | bloomberg.comAmylyx to Pull ALS Drug From Market After Failed TrialApril 4, 2024 | finance.yahoo.comUPDATE 1-Amylyx Pharma to remove ALS drug from US, Canada marketsApril 4, 2024 | finance.yahoo.comALS drug will be pulled from US market after study showed patients didn't benefitApril 4, 2024 | prnewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AmylyxApril 4, 2024 | barrons.comAmylyx Is Cutting 70% of Its Workforce and Pulling ALS Drug From the MarketApril 4, 2024 | reuters.comAmylyx Pharmaceuticals to remove ALS drug from US, Canada marketsApril 4, 2024 | businesswire.comAmylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and StrategyApril 3, 2024 | prnewswire.comShareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address Guard Against the Coming Financial Upheaval (Ad)America’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economic plot underway. That’s why if you have any savings in the bank or own any assets you want to protect, you must watch this new documentary before it’s too late. You can stream it for free right here. AMLX Media Mentions By Week AMLX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMLX News Sentiment▼0.140.42▲Average Medical News Sentiment AMLX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMLX Articles This Week▼86▲AMLX Articles Average Week Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OptiNose News Today Context Therapeutics News Today Karyopharm Therapeutics News Today PDS Biotechnology News Today Nuvectis Pharma News Today Vistagen Therapeutics News Today Cartesian Therapeutics News Today DiaMedica Therapeutics News Today Coya Therapeutics News Today Seres Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMLX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersDon’t expose yourself to stocks during the weekDTIRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHas Trump Finally Gone Too Far?Insiders ExposedDoes this make you sick?Allegiance GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHow this is some devastating newsWealthPress Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
